cb1-in-2

CB1-IN-2 (Compound 4g) is a potent and selective inhibitor of the CB1 receptor, exhibiting an IC50 value of 0.644 μM. This compound possesses the ability to penetrate the blood-brain barrier and has the potential to induce central nervous system (CNS) side effects similar to Rimonabant [1].

ABCB1-IN-2 (compound 16q) 作为一种功能性抑制剂，它能直接作用于ABCB1蛋白并稳定其结构，而不干扰ABCB1的表达和亚细胞性定位。此化合物能有效增强MCF-7/ADR细胞对紫杉醇（PTX）的反应，通过增加PTX的内部积累并抑制ABCB1介导的荧光素Rh123的积累与排出。因此，ABCB1-IN-2展现出其强大的逆转多药耐药（MDR）能力，具有作为MDR逆转剂的潜力。

GP 1a 是cannabinoid receptor 2（CB2）的强效激动剂（EC50=7.1),是在cAMP、GTPγS 和β-arrestin 招募试验中显示的。GP 1a 对CB2受体的选择性约为CB1受体的30倍，且在体外增加HL-60细胞的P-ERK1/2表达。GP 1a 对皮肤伤口愈合有益。GP 1a 可抑制炎症和纤维生成，同时促进上皮的重新形成。

COR659 是一种有效的 GABAB 的阳性变构调节剂。COR659具有缓解大鼠对酒精和巧克力成瘾的作用。

Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide) 是一种免疫调节剂，通过大麻素受体 CB1 和 CB2 起作用，还通过中枢神经系统中的其他靶点起作用，如 GPR18/GPR55。

CB1 antagonist 2 (AM4113) 是一种 caimabinoid 1 拮抗剂，在体内抑制 CB1 的IC50值为 25.5 nM。

Parecoxib sodium是一种Valdecoxib的前药，也是选择性和口服活性的COX-2抑制剂，能够抑制前列腺素(PG)的合成和缓解疼痛与炎症。Parecoxib sodium也是一种大麻素1（CB1）激动剂(EC50=2.4 µM)。

Compound 5.3 (CB1/2 receptor-1)为CB1/2受体激动剂，常用于血管生成领域的研究。

(±)5(6)-EET Ethanolamide 是 Anandamide 经细胞色素 P450 酶氧化后生成的代谢产物，同时也是一种具选择性的选择性大麻素受体 2 (CB2) 激动剂。其对人类 CB1 和 CB2 的 Ki 值分别为 11.4 μM 和 8.9 nM。该化合物可用于研究免疫调节和神经炎症。

Ibipinabant (SLV319) 是一种有效，选择性和具有口服活性的大麻素 CB1 受体 (cannabinoid CB1 receptor) 的拮抗剂，Ki 值为 7.8 nM。Ibipinabant 对 CB1 的选择性超过 CB2 (Ki=7943 nM) 的 1000 倍以上。Ibipinabant 可用于肥胖和糖尿病的研究。

O-2050 是一种高亲和力的大麻素CB1受体拮抗剂，Ki 为 2.5 nM。O-2050 抑制大麻素 CB2受体，Ki 为 0.2 nM。O-2050 减少了小鼠的食物摄入量，并且引起小鼠运动。

SCH-336是一种 CB2受体激动剂(Ki-1.8 nM, EC50-2 nM)，具有有效性，选择性和口服活性。SCH-336对 CB1受体也具有生物活性，对CB2受体的选择性是CB1的100倍。SCH-336能够减少鸟苷5'-3- o -(硫)三磷酸与含hCB 的膜的结合，抑制 BaF3/CB2 细胞迁移，抑制小鼠延迟型超敏反应模型中的白细胞迁移，抑制小鼠过敏模型中抗原诱导的肺嗜酸性粒细胞增多。

LEI-101 是有效的、选择性的、具有口服活性的大麻素CB2受体激动剂。LEI-101对 hCB2 的 pEC50值为 8，对 hERG 的 pKi 值小于 4。LEI-101 与 CB2 受体的结合能力比 CB1 强100 倍。LEI-101 具有炎症及氧化应激相关疾病的治疗潜力。

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position. O-7460 is a selective inhibitor of 2-AG biosynthesis via DAGLα (IC50 = 690 nM). It demonstrates much weaker inhibition towards human monoacylglycerol lipase and rat brain fatty acid amide hydrolase (IC50s > 10 μM) and does not bind to CB1 or CB2 cannabinoid receptors (Kis > 10 μM). At 0-12 mg/kg, i.p. in mice, O-7460 was reported to dose-dependently inhibit high-fat diet intake and reduce body weight.

URB754 is a potent and noncompetitive inhibitor of monoacylglycerol lipase (MAGL), exhibiting an IC50 value of 200 nM for the recombinant rat brain enzyme. However, it does not inhibit human recombinant, rat brain, or mouse brain MAGL at concentrations up to 100 μM. There is evidence that the MAGL inhibitory activity of URB754 may be attributed to the impurity bis(methylthio)mercurane (IC50 = 11.9 nM for rat recombinant MAGL) that is found in commercial preparations. URB754 inhibits rat brain fatty acyl amide hydrolase (FAAH) with an IC50 value of 32 μM and binds weakly to the rat central cannabinoid (CB1) receptor with an IC50 value of 3.8 μM. It does not inhibit COX-1 or COX-2 at concentrations up to 100 μM. Inhibition of MAGL hydrolysis of 2-arachidonoyl glycerol (2-AG) is associated with enhanced stress-induced analgesia and may represent a novel drug target in pain and stress management.

Anandamide (arachidonoyl ethanolamide; AEA) is an endogenous lipid with cannabinergic activity; along with 2-arachidonoyl glycerol, it forms part of the endocannabinoid system. AEA undergoes reuptake into neurons by a facilitated process. Controversy exists as to whether there is a specific AEA transporter, or instead the uptake process is simply driven by hydrolysis of AEA by intracellular fatty acyl amide hydrolase (FAAH). CAY10412 is an analog of AEA that has no intrinsic binding affinity for either CB1 or CB2 receptors. It is a potent inhibitor of AEA reuptake in U937 lymphoma cells, with an IC50 of 3 μM. CAY10412 could be a useful tool for distinguishing the competing transporter theories. The pharmacology of CAY10412 is largely unexplored; it may enhance endocannabinoid signalling by augmenting endocannabinoid concentrations.

Noladin ether (2-AG ether) 是一种具有选择性和高效性的大麻素 CB1 受体激动剂，通过非 CB1/CB2 G（i/o） 连接受体减弱大鼠离体肠系膜动脉床中的感觉神经传递，以浓度依赖性方式减弱感觉神经源性松弛。

Arachidonoyl 2-chloroethylamide (ACEA) is a potent and selective cannabinoid (CB) receptor 1 agonist with Ki values of 1.4 and >2,000 nM for CB1 and CB2 receptors, respectively. In whole animal experiments, ACEA induces hypothermia in mice with the same efficacy as arachidonoyl ethanolamide , in spite of its higher affinity for the CB1 receptor. These data have been interpreted to indicate that ACEA may be a substrate for fatty acid amide hydrolase (FAAH), and thus only transiently available in whole animal experiments.

(±)-WIN 55,212-2 is a potent aminoalkylindole cannabinoid (CB) receptor agonist with a Ki value of 62.3 and 3.3 nM for human recombinant central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively. In contrast, the enantiomer (-)-WIN 55,212-3 acts a partial inverse agonist at CB1 (pIC50 = 5.5) and as a competitive neutral antagonist of CB2, reversing the inverse agonism evoked by SR 144528 (pEC50 = 5.3). (+)-WIN 55,212 (mesylate) is a mixture of the two enantiomers, (+)-WIN 55,212-2 and (-)-WIN 55,212-3.

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1/2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

N-(1-(3,4-Dihydroxyphenyl)propan-2-yl)oleamide binds to the cannabinoid 1 (CB1) receptor with a Ki value of 365 nM in a radioligand binding assay using rat brain homogenate. It has an EC50 value of 698 nM for the peroxisome proliferator-activated receptor α (PPARα) in a luciferase reporter assay and, in rats, it decreases food intake. It does not inhibit fatty acid amide hydrolase (FAAH).

CB1-IN-1 (DBPR211) 是新型的外周大麻素-1受体 (CB1R) 拮抗剂，作用于CB1R (EC50 = 3 nM) 和 CB2R 的Ki 分别为0.3 nM 和 21 nM。

CB1/2 agonist 2 (compound 23) 是一种有效的非选择性大麻素 (cannabinoid) 配体，其Ki 分别为 3.5 nM 和 1.2 nM。CB1/2 agonist 2 是一种 CB1 的完全激动剂，也是 CB2 竞争性反向激动剂。CB1/2 agonist 2 表现出抗伤害效果。